SMS Pharmaceuticals Reports Strong Q2 Growth and Revised Outlook

Revenue stood at Rs 316.08 crore; PAT reached Rs 39.57 crore for the quarter.

Reader Takeaway: Improved operating margins and an upgraded annual outlook suggest strong momentum, though execution of large capex remains key.

What just happened

SMS Pharmaceuticals delivered a strong performance for the quarter ended September 30, 2026. Revenue climbed 30% year-on-year to Rs 316.08 crore, while EBITDA grew 40% to Rs 67.65 crore. The company’s net profit (PAT) increased significantly by 57% to Rs 39.57 crore. EBITDA margins expanded to 21%, a 145 basis point improvement, signaling effective cost management and operational efficiency.

Why this matters

Management has officially upgraded its guidance for FY27, stating that both revenue growth and EBITDA margins are now expected to exceed previous forecasts. This confidence is rooted in the company's shift toward a high-value product mix and successful backward integration strategies that protect gross margins against raw material volatility.

What changes now

Capacity expansion is the primary focus. The ongoing Rs 280 crore capital expenditure program is on track for completion by the end of FY27. This investment supports API pipeline development and a new greenfield project. Additionally, the new Peptides R&D facility is now operational, with pilot production expected by Q4FY27.

Risks to watch

Investors should monitor the execution timeline of the current Rs 280 crore capex. Any delays in the commercialization of the Peptides segment or the commissioning of new facilities could impact the company’s ability to meet its upgraded annual targets. Reliance on external market demand for APIs also remains a factor.

What to track next

The company has completed 6 DMF/CEP filings in FY27 and is on track for 10 for the full year. Watch for progress in the CRO segment, with initial revenue from the Peptides facility expected in Q2FY28.